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adjust the blood pressure level—so to speak—to 
the patient in front of you. I think all these big 
words about how low should you go, what is ac‑
ceptable, usually are not a big issue for the clini‑
cian, because the clinician tries to do a good job 
and obviously knows that the blood pressure can 
be too low. You will know a blood pressure of 0 
has a 100% mortality, so there must be a J curve, 
somewhere around blood pressure is too low, and 
morbid events will increase. It is as simple as that.
Very informative again. One, I hope, practical ques‑
tion—and I know it is really hard to describe the pa‑
tient—but reflecting on the SPRINT trial,1 reflecting 
on all the things such as how the blood pressure was 
measured in this trial, let’s say that if we were to use 
it literally, we have some evidence that going low, 
around 120 mm Hg, may be beneficial, but we consid‑
er hypertension to start at 140 mm Hg. The question 
would be: in front of you there is a patient with a ma‑
jor cardiovascular risk factor and blood pressure of 
135 mm Hg, not yet hypertensive but higher than what 
we know the SPRINT trial1 target would be. I am not 
sure whether the question is clear, but what would 
be your thinking in such cases?
The question is: should we treat normotensive pa‑
tients with antihypertensive drugs?
That is correct. How we define hypertension today.
Right. We define hypertension still as a blood 
pressure above 140 over 90 mm Hg. When you 
look at the HOPE ‑3 trial,2-4 there was no effect 
with candesartan/hydrochlorothiazide in such pa‑
tients. When you look at the SPRINT trial,1 which 
was chlorthalidone ‑based, there was an effect, so 
to speak. So is it the difference between chlortha‑
lidone and hydrochlorothiazide? We wrote a letter 
to the editor of the New England Journal of Med-
icine on this issue and I do not know whether it 
is that or not. It is very hard to say.
What we should do in any case in that patient is 
put him or her on a statin. There is no question 
During your lecture at 2016 McMaster Course in In‑
ternal Medicine in Kraków, Poland, you presented 
some data from the SPRINT trial1 and I see that my 
colleagues and myself are struggling these days with 
2 questions. Question 1: When to start treatment of 
hypertension? Question 2: What to target as a level? 
I wonder if you could expand on that.
When you have a patient sitting in front of you, 
you may ask the question: should I treat or should 
I not treat. That is a fairly common question. This 
patient is, let’s say, 35 years old, his blood pres‑
sure is around 140 over 90 mm Hg. Should I ex‑
pose this patient to antihypertensive therapy or 
not? To my way of thinking, usually I rather shoot 
first and ask questions later. In other words, if I 
tell this patient: “Look, you should lose weight, 
you should go on a low ‑salt diet, you should ex‑
ercise more, and then come back in 6 months,” I 
have lost 6 months, because he or she comes back 
and is exactly the same shape as before. I rather 
tell this patient: “Let’s start you on an angioten‑
sin receptor blocker (ARB) and blood pressure 
will be down. And now that the blood pressure 
is down, you continue exercise, or you start ex‑
ercise, you lose weight, you restrict your salt in‑
take, and if that all has happened in 6 months, I 
will be perfectly happy to take you off the anti‑
hypertensive drugs.” That is a fairly easy way to 
proceed with a patient.
The other question is: how low should you go? 
Is the right way of thinking much more a popu‑
lation question than an individual patient ques‑
tion? Because as you look at the patient, you try 
to do the best you can so that the patient does not 
have any side effects. Obviously, if the patient is 
87 years old and comes in with a blood pressure 
of 170 over 90 mm Hg, you will never go to 120 
over 70 mm Hg in such cases. It is just not feasible.
Unless you want to harm them?
Unless you want to harm them. The patient will 
be harmed. He or she will have a hip fracture 
at night, getting up and falling on the floor. You 
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about that. That will reduce stroke, heart attack, 
and death, as shown in the HOPE ‑3 study, even 
if low ‑density lipoprotein cholesterol is nor‑
mal, even if blood pressure is normal. Instead 
of thinking antihypertensive, maybe we should 
think statins.
If we decide to use an antihypertensive agent, it 
should be low ‑dose chlorthalidone or indapamide 
rather than hydrochlorothiazide.
Rather than hydrochlorothiazide. Maybe a low 
dose of amlodipine of 2.5 mg—that is very well 
tolerated in general.
Amazingly practical information. Thank you very much 
for these answers.
McMaster Perspective This interview is part of 
the McMaster Perspective collection. The video 
can be viewed at www.mcmtextbook.com. Pub‑
lished with modifications with permission from 
Dr. Franz H. Messerli.
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